| News

DayOne gains importance

08.08.2019

DayOne, a BaselArea.swiss initiative, is creating a world-leading healthcare innovation hub based on the strengths of the Basel region. A further important partner has joined to help achieve this goal.

The Department of Biosystems (D-BSSE) in Basel, which is part of the Federal Institute of Technology in Zurich (ETH), has become the latest partner of DayOne, according to a statement. With the partnership, the department will help promote digital healthcare applications and create a world-leading center for precision medicine.

Its goals are in line with those of BaselArea.swiss, which operates the DayOne initiative. BaselArea.swiss has access to sector and technology experts, doctors and scientists, and is planning to exploit the know-how of around 2,000 healthcare innovators currently based in the Basel region.

The initiative DayOne has six core activities – among them supporting the existing network, launching pioneering projects and providing collaborative workspaces. Another aspect is helping companies from abroad to settle in the Basel region, which BaselArea.swiss specializes in. Furthermore the initiative announced news concerning the other two core activities.

On September 9, the next DayOne Conference will be held at the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) in Muttenz in the canton of Basel-Landschaft. Entitled “Shaping the Future of Health”, the conference is expected to attract around 400 innovators, patients and experts. It will look at topics including digitalization and ethics, and will showcase innovations from the DayOne Accelerator and others.

The accelerator is the initiative’s sixth core activity. BaselArea.swiss and the partner organizations received more than 150 applications for the accelerator, twice as many as last year. The 16 companies considered for the first round of the accelerator can present their projects at the DayOne Conference. Four companies will then be selected for funding under the accelerator from January 2020.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

VectivBio secures investments totaling 110 million dollars
Basel Area Business & Innovation, Innovation, Invest

VectivBio secures investments totaling 110 million dollars

The Basel-based biotechnology firm VectivBio has received a capital injection of 110 million US dollars from both new and existing...

Read More
Polyphor receives up to 18 million dollars for development of antibiotics
Basel Area Business & Innovation, Innovation, Invest

Polyphor receives up to 18 million dollars for development of antibiotics

The Allschwil-based company Polyphor has received a second funding award from the global consortium CARB-X to combat antimicrobial resistance. Polyphor...

Read More
What makes Switzerland’s economy resilient in face of COVID pandemic
Basel Area Business & Innovation, Invest

What makes Switzerland’s economy resilient in face of COVID pandemic

The COVID-19 pandemic has hit economies worldwide – and we have not yet overcome it. However, Switzerland is among the...

Read More
DayOne Accelerator applications open
Basel Area Business & Innovation, Innovation

DayOne Accelerator applications open

We are excited to announce the opening of the call for the DayOne Accelerator, now in its 3rd year!

Read More
Matériaux Sabag printing concrete elements
Basel Area Business & Innovation, Innovation, Invest

Matériaux Sabag printing concrete elements

The Jura-based company Matériaux Sabag is now using a 3D printing solution to produce its concrete elements. This approach allows...

Read More
Six companies win the i4Challenge
Basel Area Business & Innovation, Innovation

Six companies win the i4Challenge

The i4Challenge expert jury has selected six winners from 18 finalists. The Industry 4.0 solutions range from 3D printing, IoT,...

Read More
Monte Rosa Therapeutics banks 96 million US dollars
Basel Area Business & Innovation, Innovation, Invest

Monte Rosa Therapeutics banks 96 million US dollars

The Basel-based biotechnology firm Monte Rosa Therapeutics has raised a total of 96 million US dollars after closing a successful...

Read More
Roche launches new coronavirus antibody test
Basel Area Business & Innovation, Innovation, Invest

Roche launches new coronavirus antibody test

Roche is launching on the market a new antibody test to determine coronavirus infections. This should help with the development...

Read More
Investors see great potential in Polyneuron
Basel Area Business & Innovation, Innovation, Invest

Investors see great potential in Polyneuron

The Basel-based company Polyneuron Pharmaceuticals extended its Series A funding round and has now raised a total of 36.5 million...

Read More
Lonza set to manufacture coronavirus drug for Humanigen
Basel Area Business & Innovation, Innovation, Invest

Lonza set to manufacture coronavirus drug for Humanigen

The Basel-based pharmaceutical supplier Lonza is supporting the US firm Humanigen in the development of a potential coronavirus therapeutic. Lonza...

Read More
1 2 3 21

Do you have a question? We'd like to hear from you.